10-9-03

CKET NO.: UNGR-1598

OCT 1 5 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger, et al.

Confirmation No.: 8248

Application No.: 09/699,679

Group Art Unit: 1617

Filing Date: October 30, 2000

Examiner: Shahnam J. Sharareh

NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND

THERAPEUTIC USE

EXPRESS MAIL LABEL NO: EV325642879US

DATE OF DEPOSIT: Oct 8,200 3

EV325642879US

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or DOCKET NO.: UNGR-1598 -2- PATENT

	before the mailing date	e of a first Office Action after the filing of request for
	continued examination	under § 1.114, no additional fee is required.
	In accordance with § 1	.129(a), this Information Disclosure Statement is being
	filed in connection wi	th [] the first or [] second After Final Submission
	therefore:	
	Certifica	tion in Accordance with § 1.97(e) is attached; or
	The fee	of \$180.00 as set forth in § 1.17(p) is attached.
\boxtimes	In accordance with § 1	.97(c), this Information Disclosure Statement is being
	filed after the period se	t forth in § 1.97(b) above but before the mailing date of
	either a Final Action ur	nder § 1.113 or a Notice of Allowance under § 1.311, or
	before an action that of	herwise closes prosecution in the application, therefore:
	\boxtimes	Certification in Accordance with § 1.97(e) is attached
		or .
		The fee of \$180.00 as set forth in § 1.17(p) is attached.
	In accordance with § 1	.97(d), this Information Disclosure Statement is being
	filed after the mailing of	date of either a Final Action under § 1.113 or a Notice
	of Allowance under §	1.311 but before, or simultaneously with, the payment
	of the Issue Fee, there	fore included are: Certification in Accordance with §
	1.97(e); and the submis	sion fee of \$180.00 as set forth in § 1.17(p).
\boxtimes	Copies of each of the	references listed on the attached Form PTO-1449 are
	enclosed herewith.	

DOCKET NO.: UNGR-1598 -3- PATENT

Copie	es of references listed on the attached Form PTO-1449 are enclosed	
herew	vith	
Copies of references listed on the attached Form PTO 1449 are not required to		
be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR §		
1.98(a)(2)(i).		
EXCEPT THAT:		
	In view of the voluminous nature of references [list as appropriate],	
	and the likelihood that these references are available to the Examiner,	
	copies are not enclosed herewith.	
	In accordance with § 1.98(d), copies of the following references listed	
	on the attached Form PTO-1449 are not enclosed herewith because	
	they were previously cited by or submitted to the U.S. Patent and	
	Trademark Office in patent application(s) for which a claim for priority	
 -	under 35 U.S.C.§ 120 have been made in the instant application:	
	Copies of references [list as appropriate] listed on the	
	attached Form PTO-1449 were previously cited by or submitted	
	to the Patent and Trademark Office in prior Application No.	
	filed	

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the PCT International Search Report dated September 17, 2003 (number 570 on the Form PTO-1449), which indicates the references considered to be relevant.

DOCKET NO.: UNGR-1598

-4
The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Date: Oct ₹ 200 \$


Legie E. Aberman
Registration No. 54,836

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103

© 2003 WW

Telephone: (215) 568-3100 Facsimile: (215) 568-3439





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger, et al.

Confirmation No.: 8248

Application No.: 09/699,679

Group Art Unit: 1617

Filing Date: October 30, 2000

Examiner: Shahnam J. Sharareh

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND

THERAPEUTIC USE

EXPRESS MAIL LABEL NO: EV325642879US DATE OF DEPOSIT: Oct 8, 200\$

PLACE EXPRESS MAIL LABEL PEEL OFF STICKER HERE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

In accordance with 37 CFR § 1.97(e), certification is hereby made that:

\boxtimes	Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
П	No item of information contained in the Information Disclosure Statement was

cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after

making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in $\S 1.56(c)$ more than three months prior to the filing of the information disclosure statement.

Date: (

Oct 8, 2003

slie E. Aberman

Registration No. 54,836

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2003 WW